These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33098047)

  • 21. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
    Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
    Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
    Michaelson MD; Gupta S; Agarwal N; Szmulewitz R; Powles T; Pili R; Bruce JY; Vaishampayan U; Larkin J; Rosbrook B; Wang E; Murphy D; Wang P; Lechuga MJ; Valota O; Shepard DR
    Oncologist; 2019 Sep; 24(9):1151-e817. PubMed ID: 31171735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
    Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
    Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
    Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER
    Cancer; 2019 Jul; 125(14):2400-2408. PubMed ID: 30951193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
    Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
    Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year survival in patients with cytokine-refractory metastatic renal cell carcinoma treated with axitinib.
    Rini BI; de La Motte Rouge T; Harzstark AL; Michaelson MD; Liu G; Grünwald V; Ingrosso A; Tortorici MA; Bycott P; Kim S; Bloom J; Motzer RJ
    Clin Genitourin Cancer; 2013 Jun; 11(2):107-14. PubMed ID: 23391371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma.
    Yamamoto Y; Otori T; Inoue R; Yano S; Hirata H; Matsumoto H; Matsuyama K; Matsuyama H
    J Clin Pharmacol; 2020 Feb; 60(2):256-263. PubMed ID: 31538342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
    Park I; Lee HJ; Bae WK; Yoon S; Lee JL
    Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
    Karam JA; Devine CE; Urbauer DL; Lozano M; Maity T; Ahrar K; Tamboli P; Tannir NM; Wood CG
    Eur Urol; 2014 Nov; 66(5):874-80. PubMed ID: 24560330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results.
    Facchini G; Rossetti S; Berretta M; Cavaliere C; Scagliarini S; Vitale MG; Ciccarese C; Di Lorenzo G; Palesandro E; Conteduca V; Basso U; Naglieri E; Farnesi A; Aieta M; Borsellino N; La Torre L; Iovane G; Bonomi L; Gasparro D; Ricevuto E; De Tursi M; De Vivo R; Lo Re G; Grillone F; Marchetti P; De Vita F; Scavelli C; Sini C; Pisconti S; Crispo A; Gebbia V; Maestri A; Galli L; De Giorgi U; Iacovelli R; Buonerba C; Cartenì G; D'Aniello C
    J Transl Med; 2019 Aug; 17(1):296. PubMed ID: 31464635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
    Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.
    Negrier S; Rioux-Leclercq N; Ferlay C; Gross-Goupil M; Gravis G; Geoffrois L; Chevreau C; Boyle H; Rolland F; Blanc E; Ravaud A; Dermeche S; Flechon A; Albiges L; Pérol D; Escudier B;
    Eur J Cancer; 2020 Apr; 129():107-116. PubMed ID: 32146304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
    Rini BI; Garrett M; Poland B; Dutcher JP; Rixe O; Wilding G; Stadler WM; Pithavala YK; Kim S; Tarazi J; Motzer RJ
    J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
    Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
    Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
    [No Abstract]   [Full Text] [Related]  

  • 35. Axitinib as a third or further line of treatment in renal cancer: a single institution experience.
    Tsironis G; Liontos M; Kyriazoglou A; Koutsoukos K; Tsiara A; Kaparelou M; Zakopoulou R; Cohen A; Skafida E; Fontara S; Zagouri F; Bamias A; Dimopoulos MA
    BMC Urol; 2020 Jun; 20(1):60. PubMed ID: 32487200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non-clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus.
    Park I; Lee SH; Lee JL
    Clin Genitourin Cancer; 2018 Oct; 16(5):e997-e1002. PubMed ID: 29903415
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma.
    Nozawa M; Sugimoto K; Ohzeki T; Minami T; Shimizu N; Adomi S; Saito Y; Nose K; Yoshimura K; Uemura H
    Int J Clin Oncol; 2016 Aug; 21(4):748-755. PubMed ID: 26694813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
    Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data.
    Sheng X; Bi F; Ren X; Cheng Y; Wang J; Rosbrook B; Jiang M; Guo J
    Future Oncol; 2019 Jan; 15(1):53-63. PubMed ID: 30058839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous collagenous vasculopathy induced by the vascular endothelial growth factor receptor inhibitor axitinib.
    Matsuzaki Y; Takahashi M; Minakawa S; Jin K; Nakano H; Sawamura D
    Int J Dermatol; 2018 Dec; 57(12):e167-e169. PubMed ID: 30229881
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.